Literature DB >> 15273748

Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency.

Minoru Tahara1, Robert G Pergolizzi, Hiroyasu Kobayashi, Anja Krause, Karsta Luettich, Martin L Lesser, Ronald G Crystal.   

Abstract

X-linked immunodeficiency with hyper-IgM (HIGM1), characterized by failure of immunoglobulin isotype switching, is caused by mutations of the CD40 ligand (CD40L), which is normally expressed on activated CD4(+) T cells. As constitutive expression of CD40L induces lymphomas, we corrected the mutation while preserving the natural regulation of CD40L using pre-mRNA trans-splicing. Bone marrow from mice lacking CD40L was modified with a lentivirus trans-splicer encoding the normal CD40L exons 2-5 and was administered to syngenic CD40L-knockout mice. Recipient mice had corrected CD40L mRNA, antigen-specific IgG1 responses to keyhole limpet hemocyanin immunization, regulated CD4(+) T-cell CD40L expression after CD3 stimulation in primary and secondary transplanted mice, attenuation of Pneumocystis carinii pneumonia, and no evidence of lymphoproliferative disease over 1 year. Thus, HIGM1 can be corrected by CD40L trans-splicing, leading to functional correction of the genetic defect without the adverse consequences of unregulated expression of the CD40L gene.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273748     DOI: 10.1038/nm1086

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  32 in total

1.  Using 5'-PTMs to repair mutant beta-globin transcripts.

Authors:  Monique N Kierlin-Duncan; Bruce A Sullenger
Journal:  RNA       Date:  2007-06-07       Impact factor: 4.942

2.  CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.

Authors:  Fatih M Uckun; Sanjive Qazi; Hong Ma; Gregory H Reaman; Lloyd G Mitchell
Journal:  Integr Biol (Camb)       Date:  2015-02       Impact factor: 2.192

3.  Replacement of huntingtin exon 1 by trans-splicing.

Authors:  Hansjörg Rindt; Pei-Fen Yen; Christina N Thebeau; Troy S Peterson; Gary A Weisman; Christian L Lorson
Journal:  Cell Mol Life Sci       Date:  2012-07-20       Impact factor: 9.261

4.  Cis-splicing and translation of the pre-trans-splicing molecule combine with efficiency in spliceosome-mediated RNA trans-splicing.

Authors:  François Monjaret; Nathalie Bourg; Laurence Suel; Carinne Roudaut; Florence Le Roy; Isabelle Richard; Karine Charton
Journal:  Mol Ther       Date:  2014-03-12       Impact factor: 11.454

Review 5.  Evolving Gene Therapy in Primary Immunodeficiency.

Authors:  Adrian J Thrasher; David A Williams
Journal:  Mol Ther       Date:  2017-03-31       Impact factor: 11.454

6.  Optimization of SMN trans-splicing through the analysis of SMN introns.

Authors:  Monir Shababi; Christian L Lorson
Journal:  J Mol Neurosci       Date:  2011-08-09       Impact factor: 3.444

Review 7.  The hyper IgM syndromes.

Authors:  Nashmia Qamar; Ramsay L Fuleihan
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

Review 8.  Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases.

Authors:  Fabio Candotti
Journal:  Int J Hematol       Date:  2014-02-01       Impact factor: 2.490

9.  Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing.

Authors:  Teresa Rodriguez-Martin; Karen Anthony; Mariano A Garcia-Blanco; S Gary Mansfield; Brian H Anderton; Jean-Marc Gallo
Journal:  Hum Mol Genet       Date:  2009-06-04       Impact factor: 6.150

10.  Exon exchange approach to repair Duchenne dystrophin transcripts.

Authors:  Stéphanie Lorain; Cécile Peccate; Maëva Le Hir; Luis Garcia
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.